Drug Trial Radar · NCT07583849
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase III Study of HSK39004 Inhalation Powder for the Treatment of COPD
Last checked: Nov 19, 2026Latest source record: Jun 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
376
Planned (sponsor's estimate)
Start
May 24, 2026
Primary completion
Sep 30, 2027
Study completion Oct 30, 2027
Sponsor
- Lead sponsor
- Haisco Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy and safety of a 12-week administration of HSK39004 inhalation powder in clinical trial participants with COPD
Conditions
- COPD (Chronic Obstructive Pulmonary Disease)
Interventions
HSK39004 Dry Powder Inhaler SimulantDrug
HSK39004 Dry Powder Inhaler Simulants, administered via oral inhalation, 1 tablet each time, twice daily
HSK39004 Dry Powder Inhaler-0.75mgDrug
HSK39004 Dry Powder Inhaler: Inhale through the mouth, 0.75mg each time, twice a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- The ΔFEV1 AUC0-12h after the 4th week administration (the area under the curveTime frame: Week 12
- The ΔFEV1 AUC0-12h after the 4th week administration (the area under the curveTime frame: week12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University People's Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.